Juliette Cubanski

@jcubanski

Medicare expert. Associate Director, Program on Medicare Policy Part D, prescription drug policy, Medicare spending & financing, cyclist

Vrijeme pridruživanja: rujan 2011.

Tweetovi

Blokirali ste korisnika/cu @jcubanski

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @jcubanski

  1. prije 5 sati

    The specialty tier in Part D plans is for drugs that cost at least $670 per month & beneficiaries typically face the highest out-of-pocket costs for drugs on this tier. Adding a new specialty tier with a lower cost-sharing requirement could provide cost relief for some people.

    Prikaži ovu nit
    Poništi
  2. prije 5 sati

    NEW from CMS: a proposal to allow Medicare Part D plans to have *2* specialty tiers. Right now plans have one specialty tier, with cost sharing ranging from 25%-33%. The proposal would allow for a new "preferred" specialty tier with lower cost sharing.

    Prikaži ovu nit
    Poništi
  3. proslijedio/la je Tweet
    prije 9 sati

    Our newest brief digs into CMS guidance inviting states to apply for waivers that would cap federal financing & authorize adult coverage without many existing standards about eligibility, benefits, delivery systems, & oversight.

    Poništi
  4. proslijedio/la je Tweet
    prije 10 sati

    Today's congressional hearing on women's was very informative! Great to learn more about work of , , . Written testimony of on USG role in this area, inc. $ and challenges, is on site 👇

    Poništi
  5. prije 11 sati

    Unless stellar economic growth boosts payroll tax levels in such a way as to push the Medicare Part A trust fund insolvency date out for several years, whoever occupies the White House for the next four years is probably going to have to confront this issue (along with Congress).

    Poništi
  6. 30. sij

    And obviously there's other stuff going on in DC that people may be hearing more about than the House-passed legislation to lower drug costs.

    Prikaži ovu nit
    Poništi
  7. 30. sij

    Of course, passing a bill through one chamber of Congress is not the same as actually lowering drug costs. Until people see their drug costs go down, perhaps they can be forgiven for not really taking notice of the legislative machinery at work that could help make that happen.

    Prikaži ovu nit
    Poništi
  8. 30. sij

    According to the new tracking poll, most people say that lowering drug costs is important for Congress to work on. At the same time, very few know that the House of Representatives passed a bill to lower drug costs in December 2019.

    Prikaži ovu nit
    Poništi
  9. 28. sij

    Private plans were supposed to be a way of controlling costs, based on the idea that plan competition could drive down the cost of providing Medicare benefits. In reality, it’s more complicated than that, but based on the numbers from CBO, it’s not what sounds like is happening.

    Prikaži ovu nit
    Poništi
  10. 28. sij

    CBO has revised upward its projections of Medicare spending in the coming decade, due in part to higher-than-expected spending on Medicare Advantage in 2019/2020, driven in part by higher payment rates to plans and coding intensity for MA enrollees.

    Prikaži ovu nit
    Poništi
  11. proslijedio/la je Tweet
    20. pro 2019.

    8.30 million people have signed up for ACA coverage through the federal marketplace for 2020, down just a bit from 8.45 million last year. The ACA is stable and resilient, not failing. However, it also has limited potential to grow without strengthening.

    Poništi
  12. 20. pro 2019.

    Nice rundown of what did and (mostly) didn't result from the legislative and regulatory push to lower drug prices in 2019. The article ends on a surprisingly hopeful tone for action in 2020, though - but it's unclear if election-year politics will help or hurt this policy agenda.

    Poništi
  13. 18. pro 2019.

    The FDA's impact analysis also suggests the potential interplay between the importation proposal and the pending international reference price proposal, with the potential for the latter to reduce the potential impact of the former.

    Poništi
  14. 18. pro 2019.

    Anxiety & frustration abound about high insulin prices in the US, which are higher than in other countries. In theory, drug importation could mean savings for some insulin users, but insulin isn't allowed to be imported. (HR3 would include insulin in price negotiations, however.)

    Poništi
  15. 18. pro 2019.

    Like allowing Medicare to negotiate prices, drug importation has been discussed for years & both ideas have advanced further in recent months. But there is much uncertainty about potential savings from importation. Notably, there are no cost/benefit in today's proposed rule.

    Poništi
  16. proslijedio/la je Tweet
    18. pro 2019.

    Having reviewed HHS' drug importation proposal, it may have a hard time satisfying the statutory (21 U.S.C. 384) requirements to authorize such importation. Here's why. (1/7)

    Prikaži ovu nit
    Poništi
  17. proslijedio/la je Tweet
    17. pro 2019.

    NEW: KFF analysis on Drug Price Increases: with We looked at antiretroviral (ARV) drug price increases in Part D. ARVs are the mainstay of HIV treatment and, increasingly, prevention.

    Prikaži ovu nit
    Poništi
  18. 11. pro 2019.

    None of these bills seems destined to land on the President’s desk, but it feels like progress that these proposals have advanced even this far in the policymaking process. Yet without changes being implemented, patients aren’t likely to see much relief from rising drug costs.

    Prikaži ovu nit
    Poništi
  19. 11. pro 2019.

    Importantly, all three proposals include a cap on out of pocket drug spending for Part D enrollees and would allow enrollees to spread out their drug costs over time. This is noteworthy common ground in otherwise highly contentious policymaking territory.

    Prikaži ovu nit
    Poništi
  20. 11. pro 2019.

    The Senate Finance proposal is something of a middle ground between House Democrats and House Republicans in terms of savings provisions, with drug price inflation limits but no Medicare drug price negotiation.

    Prikaži ovu nit
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·